Research Groups

Ruud Delwel Group

Molecular genetics of AML

Our Focus

Altered enhancer activity is one of the main drivers of aberrant expression of oncogenes in a subset of patients with acute myeloid leukemia. Upon translocation we observed that enhancers that tightly regulate key-genes important for normal development, may become over-activated and cause uncontrolled expression of their “novel” target gene. We wish to unravel how translocated enhancers in malignant cells can become so-called “super-enhancers”. Using genome editing and novel expression interference technology, we wish to uncover the exact coding-regions within the enhancers and the protein machinery that cause uncontrolled activation of disease genes.

The strength of our research group and department is the excess of large numbers of vitally frozen patient samples, a genome editing core, sequencing facilities, years of experience in culturing primary AMLs cells and development/studying myeloid leukemia in vivo (mouse models).

Andrea Arricibita Varea Technician
Bas Wouters Senior Researcher
Claudia Erpelinck Technician
Dorien Pastoors Phd Student
Leonie Smeenk Post Doc
Marije Havermans Technician
Roger Mulet Lazaro Phd Student
Sophie Ottema Phd Student
Stanley van Herk  Technician
Tim Grob Phd Student
Contact Information
Ruud Delwel Oncode Investigator

More Research

Research Strategy
Our Research Focus
Over 800 scientists working under a single strategy. Oncode is all about uniting efforts and bringing focus to research.
Support Programme
Research Programmes Overview
New plans that help fulfil Oncode's objectives get our full support. Young talents are matched with mentors on the basis of their personal endeavours.